

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETARY OF THE SENATE

05 FEB 15 AM 11:02

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.P.			
2. Address <input type="checkbox"/> Check if different than previously reported 1333 New Hampshire Avenue, NW			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20036			
4. Contact Name Bill Paxon	Telephone 202-887-4000	E-mail (optional)	5. Senate ID 682-8
7. Client Name <input type="checkbox"/> Self Pharmaceutical Research and Manufacturers of America			6. House ID 31784

**TYPE OF REPORT** 8. Year 2004 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ⇨ Termination Date \_\_\_\_\_

11. No Lobbying ☐

## INCOME OR EXPENSES – Complete Either Line 12 OR Line 13

<p align="center"><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>300,000</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of methods.</p> <p><input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definition of lobbying</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6011 Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162 Internal Revenue Code</p>
---	--

Signature \_\_\_\_\_ Date February 14, 2005

Printed Name and Title Bill Paxon, Senior Advisor

---

LD-2 (REV. 6/98)

I

Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.P. Client Name Pharmaceutical Research and Manufactur

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each co** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Implementation of H.R. 1

17. House(s) of Congress and Federal Agencies contacted

☐ Check if None

U.S. House of Representatives

U.S. Senate

U.S. Department of Health & Human Services

Office of the White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Gary A. Heimberg	
Ado A. Machida	
Bill Paxon	
Paul G. Scolese	
Barney J. Skladany	
James R. Tucker, Jr.	

19. Interest of each foreign entity in the specific issues listed on line 16 above



Check if None

Signature \_\_\_\_\_ Date February 14, 20

Printed Name and Title Bill Paxon, Senior Advisor



Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.P. Client Name Pharmaceutical Research and Manufactur

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each co** information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Importation of prescription drugs

17. House(s) of Congress and Federal Agencies contacted

☐ Check if None

U.S. House of Representatives

U.S. Senate

U.S. Department of Health & Human Services

Office of the White House

18. Name of each individual who acted as a lobbyist in this issue area


Name	Covered Official Position (if applicable)
Gary A. Heimberg	
Ado A. Machida	
Bill Paxon	
Paul G. Scolese	
Barney J. Skladany	
James R. Tucker, Jr.	

19. Interest of each foreign entity in the specific issues listed on line 16 above



Check if None

Signature



Date February 14, 20

Printed Name and Title Bill Paxon, Senior Advisor

